menu
    • menu

    Looking for excipients offered by BASF? Find information on BASF's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We create chemistry for a sustainable future. In line with our corporate purpose, around 112,000 employees contribute to the success of our customers in nearly all sectors and almost every country in the world. Our broad portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. In 2015, BASF posted sales of €70 billion and income from operations before special items of app...
    We create chemistry for a sustainable future. In line with our corporate purpose, around 112,000 employees contribute to the success of our customers in nearly all sectors and almost every country in the world. Our broad portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. In 2015, BASF posted sales of €70 billion and income from operations before special items of approximately €6.7 billion. We combine economic success with environmental protection and social responsibility. Through research and innovation, we support our customers in nearly every industry.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BASFGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Carl-Bosch-Strasse 38 Ludwigshafen , Rhineland-Palatinate 67056
    Telephone
    Telephone
    +49-(0)-621-600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pharmaceutical.basf.com/global/en.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/basf-pharma-solutions/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BASF_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    🎙️Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 214

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3947

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    KFSHRC Detects 276 Fetal Disorders, Saving SAR 360M Annually
    KFSHRC Detects 276 Fetal Disorders, Saving SAR 360M Annually

    10 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/10/3023415/0/en/KFSHRC-Detects-276-Fetal-Genetic-Disorders-Through-Prenatal-Care-Saving-SAR-360-Million-Annually.html

    GLOBENEWSWIRE
    10 Feb 2025
    Share Share
    BASF Sells Food & Health Performance Ingredients to Louis Dreyfus
    BASF Sells Food & Health Performance Ingredients to Louis Dreyfus

    24 Dec 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/basf-sells-food-and-health-performance-ingredients-business-to-louis-dreyfus-company-16572

    INDPHARMAPOST
    24 Dec 2024
    Share Share
    BASF Introduces Pepsensyal Peptide For Slow-Aging Skin Care
    BASF Introduces Pepsensyal Peptide For Slow-Aging Skin Care

    23 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/basf-introduces-pepsensyal-peptide-for-slow-aging-skin-care-solutions/

    EXPRESSPHARMA
    23 Oct 2024
    Share Share
    BASF to prepare agricultural business for IPO, Bloomberg reports
    BASF to prepare agricultural business for IPO, Bloomberg reports

    18 Sep 2024

    // REUTERS

    https://www.reuters.com/markets/europe/basf-expected-announce-listing-plans-agri-chemicals-division-reports-bloomberg-2024-09-18/

    REUTERS
    18 Sep 2024
    Share Share
    German chemical sector employers, union agree 6.85% pay hike over 20 months
    German chemical sector employers, union agree 6.85% pay hike over 20 months

    27 Jun 2024

    // REUTERS

    https://www.reuters.com/markets/commodities/german-chemical-sector-employers-union-agree-685-pay-hike-over-20-months-2024-06-27/

    REUTERS
    27 Jun 2024
    Share Share
    Signet, BASF organize Formulator’s Forum: Exchange Excipients Innovation in Hyd
    Signet, BASF organize Formulator’s Forum: Exchange Excipients Innovation in Hyd

    08 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168392&sid=2

    PHARMABIZ
    08 Apr 2024
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact BASF and get a quotation

    BASF is a supplier offers 65 products (APIs, Excipients or Intermediates).

    Find a price of Ibuprofen bulk with DMF, CEP, JDMF offered by BASF

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk with DMF, CEP, JDMF offered by BASF

    Find a price of Riboflavin bulk with CEP, JDMF offered by BASF

    Find a price of Vitamin E Acetate bulk with CEP, JDMF offered by BASF

    Find a price of Icosapent Ethyl bulk with DMF, JDMF offered by BASF

    Find a price of Levomenthol bulk with DMF, CEP offered by BASF

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk with DMF, CEP offered by BASF

    Find a price of Povidone Iodine bulk with DMF, JDMF offered by BASF

    Find a price of Riboflavin bulk with JDMF offered by BASF

    Find a price of Vitamin A bulk with CEP offered by BASF

    Find a price of Vitamin E bulk with CEP offered by BASF

    Find a price of 2-Phenoxyethanol bulk with CEP offered by BASF

    Find a price of Acitretin bulk offered by BASF

    Find a price of Ascorbic Acid bulk offered by BASF

    Find a price of Azelaic Acid bulk with DMF offered by BASF

    Find a price of D-Panthenol bulk with CEP offered by BASF

    Find a price of Detalan bulk with DMF offered by BASF

    Find a price of Ibuprofen bulk with DMF offered by BASF

    Find a price of Ibuprofen Sodium bulk with DMF offered by BASF

    Find a price of Menthol bulk with JDMF offered by BASF

    Find a price of Octocrylene bulk with DMF offered by BASF

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk with DMF offered by BASF

    Find a price of Pantothenic Acid bulk with CEP offered by BASF

    Find a price of Polyethylene Glycol Monostearate bulk with DMF offered by BASF

    Find a price of Triclosan bulk with DMF offered by BASF

    Find a price of Vitamin D3 bulk with DMF offered by BASF

    Find a price of 5-Ethenyl-Pyrrolidin-2-One bulk offered by BASF

    Find a price of Benzoic Acid bulk offered by BASF

    Find a price of Beta Carotene bulk offered by BASF

    Find a price of Calcium Ascorbate bulk offered by BASF

    Find a price of DHA bulk offered by BASF

    Find a price of Diethylhexyl Phthalate bulk offered by BASF

    Find a price of Doxazosin Mesylate bulk offered by BASF

    Find a price of Fluoxetine Hydrochloride bulk offered by BASF

    Find a price of Hexanedioic Acid, Polymer With 1,6-Hexanediol bulk offered by BASF

    Find a price of Isotretinoin bulk offered by BASF

    Find a price of Macrogol bulk offered by BASF

    Find a price of Paracetamol bulk offered by BASF

    Find a price of Pyridoxine Hydrochloride bulk offered by BASF

    Find a price of Riboflavin bulk offered by BASF

    Find a price of Sibutramine Hydrochloride bulk offered by BASF

    Find a price of Sodium Ascorbate bulk offered by BASF

    Find a price of Tazarotene bulk offered by BASF

    Find a price of Terazosin HCl bulk offered by BASF

    Find a price of Thiamine Hydrochloride bulk offered by BASF

    Find a price of Thiamine Mononitrate bulk offered by BASF

    Find a price of Tretinoin bulk offered by BASF

    Find a price of Vitamin A Acetate bulk offered by BASF

    Find a price of Vitamin A Palmitate bulk offered by BASF

    Find a price of Vitamin D3 bulk offered by BASF

    Find a price of Vitamin E bulk offered by BASF

    Find a price of UVINUL N539 SG bulk offered by BASF

    Find a price of RADIO-PHARMACEUTICAL SYNTHESIS MODULE << SYNTHERArV1 >> bulk offered by BASF

    Find a price of GLUCOPONA(R) 600 UP bulk offered by BASF

    Find a price of N-[1-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL 2-NAPHTHALENYL) bulk offered by BASF

    Find a price of LUROTIN TM CAPSULES bulk offered by BASF

    Find a price of MFG SITE FACILITIES OPERATING PROCEDURES AND PERSONEL FOR OSLO NORWAY bulk offered by BASF

    Find a price of STERILE AREA 1 DEPARTMENT AT MONZA FACILITY IN MILAN, ITALY. bulk offered by BASF

    Find a price of KOLLIDON 12 PF, POLYVINYLPYRROLIDONE bulk offered by BASF

    Find a price of Bronopol bulk offered by BASF

    Find a price of Calcium Pantothenate bulk offered by BASF

    Find a price of Ibuprofen bulk offered by BASF

    Find a price of Ibuprofen Lysinate bulk offered by BASF

    Find a price of Levomenthol bulk offered by BASF

    Find a price of Zinc Oxide bulk offered by BASF

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search